Poolbeg Pharma PLC
LSE: POLB.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeremy Skillington
- Employees
- 15
- Headquarters
- London, United Kingdom
- IPO year
- 2021
- Market cap
- £30.7M
- Website
- https://www.poolbegpharma.com
Loading POLB…
Loading profile data…Frequently asked questions about POLB
What does Poolbeg Pharma PLC (POLB.L) do?
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intra...
Where does POLB.L trade?
Poolbeg Pharma PLC (POLB.L) trades on the London Stock Exchange.
What sector is POLB.L in?
Poolbeg Pharma PLC (POLB.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Poolbeg Pharma PLC?
Jeremy Skillington is the chief executive officer of Poolbeg Pharma PLC (POLB.L).
Where is Poolbeg Pharma PLC headquartered?
Poolbeg Pharma PLC is headquartered in United Kingdom.
Does POLB.L pay a dividend?
Poolbeg Pharma PLC (POLB.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did POLB.L go public?
Poolbeg Pharma PLC (POLB.L) completed its initial public offering in 2021.